Evidence map›Paper›PMID 31497344›Full record

ArticleAmerican journal of cancer research2019

RILPL2 regulates breast cancer proliferation, metastasis, and chemoresistance via the TUBB3/PTEN pathway.

Guanglei Chen, Lisha Sun, Jianjun Han, Sufang Shi, Yuna Dai, Weiguang Liu

Open access · greenAbstract read
In one paragraph

Article in American journal of cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Guanglei ChenDepartment of Breast Surgery, Shengjing Hospital of China Medical University Shenyang 110004, Liaoning Province, China.
Lisha SunDepartment of Breast Surgery, Shengjing Hospital of China Medical University Shenyang 110004, Liaoning Province, China.
Jianjun HanDepartment of Breast Surgery, Affiliated Hospital of Hebei University of Engineering Handan 056000, Hebei Province, China.
Sufang ShiDepartment of Breast Surgery, Affiliated Hospital of Hebei University of Engineering Handan 056000, Hebei Province, China.
Yuna DaiDepartment of Breast Surgery, Affiliated Hospital of Hebei University of Engineering Handan 056000, Hebei Province, China.
Weiguang LiuDepartment of Breast Surgery, Affiliated Hospital of Hebei University of Engineering Handan 056000, Hebei Province, China.
Hebei University of Engineering · CNChina Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer (BC) is the most common malignancy in women and is one of the leading causes of cancer-associated deaths. The analysis of data obtained from online databases revealed that RILPL2 expression in BC tissues is lower than that in normal tissues, and that RILPL2 upregulation is correlated with prolonged recurrence-free survival (RFS), overall survival (OS), and distant metastasis-free survival (DMFS). However, the function of RILPL2 in tumor proliferation and metastasis remains unclear. In this study, we demonstrated that RILPL2 had lower expression in BC tissues than in adjacent normal tissues, and that RILPL2 expression was significantly negatively correlated with tumor size, histological grade, and lymph node metastasis. Univariate analysis showed a positive correlation between RILPL2 and estrogen receptor (ER) expression and a negative correlation between RILPL2 and human epidermal growth factor receptor 2 (HER2) expression. Overexpression of RILPL2 inhibited BC cell proliferation and metastasis

Indexed as

Breast cancerchemoresistancemetastasisprognosisRILPL2TUBB3

Identifiers

PMID31497344
PMCPMC6726981
OpenAlexW2990132269

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.